These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 17392727)

  • 1. Developing strategies to link basic cardiovascular sciences with clinical drug development: another opportunity for translational sciences.
    Feldman AM; Koch WJ; Force TL
    Clin Pharmacol Ther; 2007 Jun; 81(6):887-92. PubMed ID: 17392727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardionomics: a new integrative approach for screening cardiotoxicity of drug candidates.
    Gwathmey JK; Tsaioun K; Hajjar RJ
    Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):647-60. PubMed ID: 19442031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.
    Telli ML; Hunt SA; Carlson RW; Guardino AE
    J Clin Oncol; 2007 Aug; 25(23):3525-33. PubMed ID: 17687157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention and management of cardiotoxicity from antineoplastic therapy.
    Chanan-Khan A; Srinivasan S; Czuczman MS
    J Support Oncol; 2004; 2(3):251-6; discussion 259-61, 264-6. PubMed ID: 15328825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological foundations of cardio-oncology.
    Minotti G; Salvatorelli E; Menna P
    J Pharmacol Exp Ther; 2010 Jul; 334(1):2-8. PubMed ID: 20335321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer.
    Fiúza M
    Adv Ther; 2009 Jul; 26 Suppl 1():S9-17. PubMed ID: 19669637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab-related cardiotoxicity in the herceptin adjuvant trial.
    Montemurro F; Redana S; Valabrega G; Martinello R; Aglietta M; Palmiero R
    J Clin Oncol; 2008 Apr; 26(12):2052-3; author reply 2053-4. PubMed ID: 18421060
    [No Abstract]   [Full Text] [Related]  

  • 9. [Cardiovascular toxicity of selective COX-2-inhibitors and classical NSAIDs].
    Lange H; Eberhart L
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2007 Jul; 42(7):514-7. PubMed ID: 17661262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative.
    Piccini JP; Whellan DJ; Berridge BR; Finkle JK; Pettit SD; Stockbridge N; Valentin JP; Vargas HM; Krucoff MW;
    Am Heart J; 2009 Sep; 158(3):317-26. PubMed ID: 19699852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiotoxicity of antitumor drugs.
    Menna P; Salvatorelli E; Minotti G
    Chem Res Toxicol; 2008 May; 21(5):978-89. PubMed ID: 18376852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contemporary pre-clinical development of anticancer agents--what are the optimal preclinical models?
    Damia G; D'Incalci M
    Eur J Cancer; 2009 Nov; 45(16):2768-81. PubMed ID: 19762228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology.
    Eschenhagen T; Force T; Ewer MS; de Keulenaer GW; Suter TM; Anker SD; Avkiran M; de Azambuja E; Balligand JL; Brutsaert DL; Condorelli G; Hansen A; Heymans S; Hill JA; Hirsch E; Hilfiker-Kleiner D; Janssens S; de Jong S; Neubauer G; Pieske B; Ponikowski P; Pirmohamed M; Rauchhaus M; Sawyer D; Sugden PH; Wojta J; Zannad F; Shah AM
    Eur J Heart Fail; 2011 Jan; 13(1):1-10. PubMed ID: 21169385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reader comments on complementary and alternative medicine programs.
    Lee CO
    Clin J Oncol Nurs; 2005 Oct; 9(5):510; author reply 510-1. PubMed ID: 16235577
    [No Abstract]   [Full Text] [Related]  

  • 15. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and planned clinical trials with trastuzumab (Herceptin).
    Baselga J
    Semin Oncol; 2000 Oct; 27(5 Suppl 9):27-32. PubMed ID: 11049054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiotoxicity associated with targeting kinase pathways in cancer.
    Mellor HR; Bell AR; Valentin JP; Roberts RR
    Toxicol Sci; 2011 Mar; 120(1):14-32. PubMed ID: 21177772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy.
    Raschi E; Vasina V; Ursino MG; Boriani G; Martoni A; De Ponti F
    Pharmacol Ther; 2010 Feb; 125(2):196-218. PubMed ID: 19874849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclooxygenase-2 inhibitors and most traditional nonsteroidal anti-inflammatory drugs cause similar moderately increased risks of cardiovascular disease.
    Hennekens CH; Borzak S
    J Cardiovasc Pharmacol Ther; 2008 Mar; 13(1):41-50. PubMed ID: 18287589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory Affairs introduction.
    Green JD
    Toxicol Pathol; 2009 Apr; 37(3):361-2. PubMed ID: 19380847
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.